Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s10020-021-00313-3 http://scihub22266oqcxt.onion/10.1186/s10020-021-00313-3 34022793!8140578!34022793     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Med 2021 ; 27 (1): 49 Nephropedia Template TP {{tp|p=34022793|t=2021. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines |pdf=|usr=}}{{34022793}} gab.com Text Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines JO: Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=34022793 #FOAvip A SARS-like coronavirus 2 (SARS-CoV-2) has caused a pandemic Coronavirus Disease 2019 (COVID-19) that killed more than 3.3 million people worldwide. Like the SARS-CoV, SARS-CoV-2 also employs a receptor-binding motif (RBM) of its spike protein to bind a host receptor, the angiotensin-converting enzyme 2 (ACE2), to gain entry. Currently, several mRNA or adenoviral vaccines encoding for the spike protein of SARS-CoV-2 are being used to boost antibodies capable of inhibiting spike-ACE2 interaction and viral entry. However, recent evidence has also suggested an anti-inflammatory effect of spike-reactive antibodies, suggesting that some SARS-CoV-2 spike-based vaccines may elicit protective antibodies capable of inhibiting GM-CSF production and COVID-19 progression. Twit Text FOAVip Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines ????Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=34022793 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34022793 #FOAvip English Wikipedia <ref>{{Cite pmid|34022793}}</ref> Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines #MMPMID34022793 Li J; Wang P; Tracey KJ; Wang H Mol Med 2021[May]; 27 (1): 49 PMID34022793show ga A SARS-like coronavirus 2 (SARS-CoV-2) has caused a pandemic Coronavirus Disease 2019 (COVID-19) that killed more than 3.3 million people worldwide. Like the SARS-CoV, SARS-CoV-2 also employs a receptor-binding motif (RBM) of its spike protein to bind a host receptor, the angiotensin-converting enzyme 2 (ACE2), to gain entry. Currently, several mRNA or adenoviral vaccines encoding for the spike protein of SARS-CoV-2 are being used to boost antibodies capable of inhibiting spike-ACE2 interaction and viral entry. However, recent evidence has also suggested an anti-inflammatory effect of spike-reactive antibodies, suggesting that some SARS-CoV-2 spike-based vaccines may elicit protective antibodies capable of inhibiting GM-CSF production and COVID-19 progression. |Angiotensin-Converting Enzyme 2/*metabolism[MESH] |Antibodies, Neutralizing/immunology/*metabolism[MESH] |COVID-19 Vaccines/immunology/*therapeutic use[MESH] |COVID-19/metabolism/*prevention & control/virology[MESH] |Granulocyte-Macrophage Colony-Stimulating Factor/*antagonists & inhibitors/metabolism[MESH] |Host-Pathogen Interactions/drug effects[MESH] |Humans[MESH] |Protein Binding/drug effects[MESH] |SARS-CoV-2/immunology/metabolism/physiology[MESH] |Spike Glycoprotein, Coronavirus/immunology/*metabolism[MESH] |Virus Internalization/drug effects[MESH]Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vac(epmc).pdf DeepDyve Pubget Overpricing